Rare adverse events associated with oral poliovirus vaccine in Brazil

Brazilian Journal of Medical and Biological Research

Volumn 30, Issue 6, 1997, Pages 695-703

  Friedrich, F ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Facial paralysis; Guillain Barre syndrome; Poliomyelitis; Poliovirus; Tranverse myelitis; Vaccine associated cases

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

BRAZIL; FACIAL NERVE PARALYSIS; GUILLAIN BARRE SYNDROME; HUMAN; INFECTION PREVENTION; MYELITIS; POLIOMYELITIS; REVIEW; VIRULENCE;

POLIOVIRUS;

EID: 0030740099     PISSN: 0100879X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0100-879X1997000600001     Document Type: Review

References (110)

1. Almond JW (1987). The attenuation of poliovirus neurovirulence. Annual Review of Microbiology, 41: 153-180.
2. Racaniello VR (1988). Poliovirus neurovirulence. Advances in Virus Research, 34: 217-246.
3. Wimmer E, Hellen CUT & Cao X (1993). Genetics of poliovirus. Annual Review of Genetics, 27: 353-436.
4. Murdin AD, Barreto L & Plotkin S (1996). Inactivated poliovirus vaccine: past and present experience. Vaccine, 14: 735-746.
5. Horaud F (1993). Albert B. Sabin and the development of oral poliovaccine. Biologicals, 21: 311-316.
6. Horaud F (1995). An historical outline of the development of live poliovaccine and its non-target effects. Developments in Biological Standardization, 84: 117-122.
7. World Health Organization (1982). The relation between acute persisting spinal paralysis and poliomyelitis vaccine - results of a ten-year enquiry. Bulletin of the World Health Organization, 60: 231-242.
8. Friedrich F (1996). Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees. Acta Virologica, 40: 157-170.
9. Minor PD (1992). The molecular biology of poliovaccines. Journal of General Virology, 73: 3065-3077.
10. Minor PD (1993). Attenuation and reversion of the Sabin vaccine strains of poliovirus. Developments in Biological Standardization, 78: 17-26.
11. Minor PD, Macadam AJ, Stone DM & Almond JW (1993). Genetic basis of attenuation of the Sabin oral poliovirus vaccines. Biologicals, 21: 357-363.
12. Chumakov K, Norwood L, Parker M, Dragunsky E, Taffs R, Ran Y, Ridge J & Levenbook I (1993). Assessment of the viral RNA sequence heterogeneity for control of OPV neurovirulence. Developments in Biological Standardization, 78: 79-89.
13. Dragunsky E, Taffs R, Chernokhvostova Y, Nomura T, Hioki K, Gardner D, Norwood L & Levenbook I (1996). A poliovirus-susceptible transgenic mouse model as a possible replacement for the monkey neurovirulence test of oral poliovirus vaccine. Biologicals, 24: 77-86.
14. Lu Z, Rezapkin GV, Douthitt MP, Ran Y, Asher DM, Levenbook IS & Chumakov KM (1996). Limited genetic changes in the Sabin 1 strain of poliovirus occurring in the central nervous system of monkeys. Journal of General Virology, 77: 273-280.
15. Lu Z, Asher DM, Levenbook IS & Chumakov KM (1996). Succession of mutations in the Sabin strain of type 3 poliovirus replicating in the central nervous system of monkeys. Virology, 220: 285-289.
16. Wright PF, Kim-Farley RJ, de-Quadros CA, Robertson SE, Scott RMN, Ward NA & Henderson RH (1991). Strategies for the global eradication of poliomyelitis by the year 2000. New England Journal of Medicine, 325: 1774-1779.
17. Hull HF, Ward NA, Hull BP, Milstien JB & de-Quadros C (1994). Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet, 343: 1331-1337.
18. Kew OM, Mulders MN, Lipskaya GY, Da-Silva EE & Pallansch MA (1995). Molecular epidemiology of polioviruses. Seminars in Virology, 6: 401-414.
19. Centers for Disease Control (1992). Update: Eradication of paralytic poliomyelitis in the Americas. Morbidity and Mortality Weekly Report, 41: 681-683.
20. Centers for Disease Control and Prevention (1994]. Certification of poliomyelitis eradication - the Americas, 1994. Morbidity and Mortality Weekly Report, 43: 720-722.
21. World Health Organization (1994). Expanded programme on immunization. Certification of poliovirus eradication - the Americas. Weekly Epidemiological Record, 69: 293-295.
22. Mulders MN, Lipskaya GY, van-der-Avoort HGAM, Koopmans MPG, Kew OM & van-Loon AM (1995). Molecular epidemiology of wild poliovirus type 1 in Europe, the Middle East, and the Indian subcontinent. Journal of Infectious Diseases, 171: 1399-1405.
23. Rico-Hesse R, Pallansch MA, Nottay BK & Kew OM (1987). Geographic distribution of wild poliovirus type 1 genotypes. Virology, 160: 311-322.
24. Zheng DP, Zhang LB, Fang ZY, Yang CF, Mulders M, Pallansch MA & Kew OM (1993). Distribution of wild type 1 poliovirus genotypes in China. Journal of Infectious Diseases, 168: 1361-1367.
25. Oostvogel PM, van-Wijngaarden JK, van-der-Avoort HGAM, Mulders MN, Conynvan Spaendonck MAE, Rümke HC, van-Steenis G & van-Loon AM (1994). Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-93. Lancet 344: 665-670.
26. van-Niekerk ABW, Vries JB, Baard J, Schoub BD, Chezzi C & Blackburn NK (1994). Outbreak of paralytic poliomyelitis in Namibia. Lancet, 344: 661-664.
27. Huovilainen A, Mulders MN, Agboatwalla M, Pöyry T, Stenvik M & Hovi T (1995). Genetic divergence of poliovirus strains isolated in the Karachi region of Pakistan. Journal of General Virology, 76: 3079-3088.
28. Li J, Yoneyama T, Yoshida H, Yoshii K, Shimizu H, Miyamura T, Hara M, Hou XH, Zheng H, Fang Y, Zhang LB & Hagiwara A (1995). Genetic analysis of wild-type 1 poliovirus isolates in China, 1985-1993. Research in Virology, 146: 415-422.
29. Lipskaya GY, Chervonskaya EA, Belova GI, Maslova SV, Kutateladze TN, Drozdov SG, Mulders M, Pallansch MA, Kew OM & Agol VI (1995). Geographical genotypes (geotypes) of poliovirus case isolates from the former Soviet Union: relatedness to other known poliovirus genotypes. Journal of General Virology, 76: 1687-1699.
30. Schonberger LB, McGowan JE & Gregg MB (1976). Vaccine-associated poliomyelitis in the United States, 1961-1972. American Journal of Epidemiology, 104: 202-211.
31. Basilico FC & Bernat JL (1978). Vaccine-associated poliomyelitis in a contact. Journal of the American Medical Association, 239: 2275.
32. Maas G & Quast U (1987). Acute spinal paralysis after the administration of oral poliomyelitis vaccine in the Federal Republic of Germany (1963-1984). Journal of Biological Standardization, 15: 185-191.
33. Nkowane BM, Wassilak SGF, Orenstein WA, Bart KJ, Schonberger LB, Hinman AR & Kew OM (1987). Vaccine-associated paralytic poliomyelitis in the United States: 1973 through 1984. Journal of the American Medical Association, 257: 1335-1340.
34. Joce R, Wood D, Brown D & Begg N (1992). Paralytic poliomyelitis in England and Wales, 1985-91. British Medical Journal, 305: 79-82.
35. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA & Hinman AR (1992). Epidemiology of poliomyelitis in the United States one decade after the last report case of indigenous wild virus-associated disease. Clinical Infectious Diseases, 14: 568-579.
36. Strebel PM, Aubert-Combiescu A, Ion-Nedelcu N, Biberi-Moroeanu S, Combiescu M, Sutter RW, Kew OM, Pallansch MA, Patriarca PA & Cochi SL (1994). Paralytic poliomyelitis in Romania, 1984-1992: Evidence for a high risk of vaccine-associated disease and reintroduction of wild-virus infection. American Journal of Epidemiology, 140: 1111-1124.
37. Andrus JK, Strebel PM, de-Quadros CA & Olivè JM (1995). Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989-91. Bulletin of the World Health Organization, 73: 33-40.
38. Driesel G, Diedrich S, Künkel U & Schreier E (1995). Vaccine-associated cases of poliomyelitis over a 30 year period in East Germany. European Journal of Epidemiology, 11: 1-8.
39. Centers for Disease Control and Prevention (1997). Paralytic poliomyelitis - United States, 1980-1994. Journal of the American Medical Association, 277: 525-526.
40. Kew OM, Nottay BK, Hatch MH, Nakano JH & Obikeski JF (1981). Multiple genetic changes can occur in the oral poliovaccines upon replication in humans. Journal of General Virology, 56: 337-347.
41. Minor PD (1982). Characterization of strains of type 3 poliovirus by oligonucleotide mapping. Journal of General Virology, 59: 307-317.
42. Cann AJ, Stanway G, Hughes PJ, Minor PD, Evans DMA, Schild GC & Almond JW (1984). Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Research, 12: 7787-7792.
43. Almond JW, Westrop GD, Cann AJ, Stanway G, Evans DMA, Minor PD & Schild GC (1985). Attenuation and reversion to neurovirulence of the Sabin poliovirus type 3 vaccine. In: Lerner RA, Chanock RM & Brown F (Editors), Vaccines 85. Cold Spring Harbor Laboratory, New York, 271-277.
44. Evans DMA, Dunn G, Minor PD, Schild GC, Cann AJ, Stanway G, Almond JW, Currey K & Maizel Jr JV (1985). Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature, 314: 548-550.
45. Fiore L, Pierangeli A, Lombardi F, Santoro R, Crainic R, Venuti A & Perez-Bercoff R (1987). Antigenic and biochemical characterization of poliovirus type 2 isolated from two cases of paralytic disease. Intervirology, 27: 196-204.
46. Minor PD, Dunn G, Evans DMA, Magrath DI, John A, Hewlett J, Phillips A, Westrop G, Wareham K, Almond JW & Hogle JM (1989). The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3. Journal of General Virology. 70: 1117-1123.
47. Pollard SR, Dunn G, Cammack N, Minor PD & Almond JW (1989). Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. Journal of Virology, 63: 4949-4951.
48. Macadam AJ, Arnold C, Howlett J, John A, Marsden S, Taffs F, Reeve P, Hamada N, Wareham K, Almond J, Cammack N & Minor PD (1989). Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology, 172: 408-414.
49. Macadam AJ, Pollard SR, Ferguson G, Dunn G, Skuce R, Almond JW & Minor PD (1991). The 5' noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology, 181: 451-458.
50. Macadam AJ, Pollard SR, Ferguson G, Skuce R, Wood D, Almond JW & Minor PD (1993). Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology, 192: 18-26.
51. Equestre M, Genovese D, Cavaliere F, Fiore L, Santoro R & Perez-Bercoff R (1991). Identification of a consistent pattern of mutations in neurovirulent variants derived from the Sabin vaccine strain of poliovirus type 2. Journal of Virology, 65: 2707-2710.
52. Lipskaya GY, Muzychenko AR, Kutitova OK, Maslova SV, Equestre M, Drozdov SG, Perez-Bercoff R & Agol VI (1991). Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine-associated polio cases. Journal of Medical Virology, 35: 290-296.
53. Muzychenko AR, Lipskaya GY, Maslova SV, Svitkin YV, Pilipenko EV, Nottay BK, Kew OM & Agol VI (1991). Coupled mutations in the 5'-untranslated region of the Sabin poliovirus strains during in vivo passages: structural and functional implications. Virus Research, 21: 111-122.
54. Furione M, Guillot S, Otelea D, Balanant J, Candrea A & Crainic R (1993). Poliovirus with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology, 196: 199-208.
55. Otelea D, Guillot S, Furione M, Combiescu AA, Balanant J, Candrea A & Crainic R (1993). Genomic modifications in naturally occurring neurovirulent revertants of Sabin 1 polioviruses. Developments in Biological Standardization, 78: 33-38.
56. Guillot S, Otelea D, Delpeyroux F & Crainic R (1994). Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction. Vaccine, 12: 503-507.
57. Georgescu MM, Delpeyroux F, Tardy-Panit M, Balanant J, Combiescu M, Combiescu AA, Guillot S & Crainic R (1994). High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. Journal of Virology, 68: 8089-8101.
58. Georgescu MM, Delpeyroux F & Crainic R (1995). Tripartite genome organization of a natural type 2 vaccine/nonvaccine recombinant poliovirus. Journal of General Virology, 76: 2343-2348.
59. Georgescu MM, Tardy-Panit M, Guillot S, Crainic R & Delpeyroux F (1995). Mapping of mutations contributing to the temperature sensitivity of the Sabin 1 vaccine strain of poliovirus. Journal of Virology, 69: 5278-5286.
60. Li J, Zhang LB, Yoneyama T, Yoshida H, Shimizu H, Yoshii K, Hara M, Nomura T, Yoshikura H, Miyamura T & Hagiwara A (1996). Genetic basis of the neurovirulence of type 1 polioviruses isolated from vaccine-associated paralytic patients. Archives of Virology, 141: 1047-1054.
61. Jiming Z (1996). Comments on some new viruses associated with old diseases in China. Chinese Medical Journal, 109: 5-10.
62. Minor PD, John A, Ferguson M & lcenogle JP (1986). Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. Journal of General Virology, 67: 693-706.
63. Cammack N, Phillips A, Dunn G, Patel V & Minor PD (1988). Intertypic genomic rearrangements of poliovirus strains in vaccinees. Virology, 167: 507-514.
64. Minor PD & Dunn G (1988). The effect of sequences in the 5'noncoding region on the replication of polioviruses in the human gut. Journal of General Virology, 69: 1091-1096.
65. Dunn G, Begg NT, Cammack N & Minor PD (1990). Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. Journal of Medical Virology, 32: 92-95.
66. Ogra PL, Faden HS, Abraham R, Duffy LC, Sun M & Minor PD (1991). Effect of prior immunity on the shedding of virulent revertant virus in faeces after oral immunization with live attenuated poliovirus vaccines. Journal of Infectious Diseases, 164: 191-194.
67. Tatem JM, Weeks-Levy C, Mento SJ, Di-Michele SJ, Georgiu A, Waterfield WF, Sheip B, Costalas C, Davies T, Ritchey MB & Cano FR (1991). Oral poliovirus vaccine in the United States: molecular characterization of Sabin type 3 after replication in the gut of vaccinees. Journal of Medical Virology, 35: 101-109.
68. Contreras G, Dimock K, Furesz J, Gardell C, Hazlett D, Karpinski K, McCorkle G & Wu L (1992). Genetic characterization of Sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract. Biologicals, 20: 15-26.
69. Abraham R, Minor P, Dunn G, Modlin JF & Ogra PL (1993). Shedding of virulent poliovirus revenants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. Journal of Infectious Diseases, 168: 1105-1109.
70. Lederman HM & Winkelstein JA (1985). X-Linked agammaglobulinemia: an analysis of 96 patients. Medicine, 64: 145-156.
71. Arya SC (1994). Vaccine-associated poliomyelitis. Lancet, 343: 610-611.
72. Groom SN, Clewley J, Litton PA & Brown DW (1994). Vaccine-associated poliomyelitis. Lancet, 343: 609-610.
73. Ion-Nedelcu N, Dobrescu A, Strebel PM & Sutter RW (1994). Vaccine-associated paralytic poliomyelitis and HIV infection. Lancet, 343: 51-52.
74. Wyatt HV (1994). Vaccine-associated poliomyelitis. Lancet, 343: 610.
75. Zuckerman MA, Brink NS, Kyi M & Tedder RS (1994). Exposure of immunocompromised individuals to health-care workers immunized with oral poliovaccine. Lancet, 343: 985-986.
76. Strebel PM, Ion-Nedelcu N, Baughman AL, Sutter RW & Cochi SL (1995). Intramuscular injections within 30 days of immunization with oral poliovirus vaccine - risk factor for vaccine-associated paralytic poliomyelitis. New England Journal of Medicine, 332: 500-506.
77. Filippis AMB, Schatzmayr HG, Ferreira FC, Chagas SAR, Costa MC, Santos AP & Da-Silva EE (1994). Intratypic differentiation of polioviruses isolated from suspected cases of poliomyelitis in Brazil during the period of 1990 to 1993. Memorias do Institute Oswaldo Cruz, 89: 513-518.
78. Friedrich F (1993). Caracterizaçāo genômica de amostras de poliovirus tipos 2 e 3 isoladas de casos de poliomielite paralítica associados a vacina Sabin no Brasil. Master's thesis. IOC/FIOCRUZ.
79. Friedrich F (1996). Modificaçȯes genâ-micas em poliovírus tipos 1, 2 e 3 derivados da vacina Sabin, isolados no Brasil. Doctoral thesis. IOC/FIOCRUZ.
80. World Health Organization (1990). Manual for Virological Investigation of Poliomyelitis. WHO/EPI/CDS/POLIO/90.1.
81. Da-Silva EE, Pallansch MA, Holloway BP, Oliveira MJC, Schatzmayr HG & Kew OM (1991). Oligonucleotide probes for the specific detection of the wild poliovirus types 1 and 3 endemic to Brazil. Intervirology 32: 149-159.
82. Yang CF, De L, Holloway BP, Pallansch MA & Kew OM (1991). Detection and identification of vaccine-related polioviruses by the polymerase chain reaction. Virus Research, 20: 159-179.
83. Da-Silva EE, Schatzmayr HG & Kew OM (1990). Nucleotide sequences of the VP1 capsid proteins of wild poliovirus types 1 and 3 from epidemic areas of Brazil. Brazilian Journal of Medical and Biological Research, 23: 1-5.
84. Friedrich F, Filippis AMB, Ferreira FC, Schatzmayr HG & Da-Silva EE (1995). Genomic characterization of type 2 polioviruses isolated from vaccine-associated cases in Brazil. Brazilian Journal of Medical and Biological Research, 28: 733-742.
85. Friedrich F, Filippis AMB, Ferreira FC, Schatzmayr HG & Da-Silva EE (1995). Genomic characterization of type 3 polioviruses isolated from vaccine-associated poliomyelitis cases in Brazil. Brazilian Journal of Medical and Biological Research, 28: 195-200.
86. Friedrich F, Filippis AMB, Ferreira FC, Oliveira MJC, Schatzmayr HG & Da-Silva EE (1996). Poliovirus type 1 isolated from a vaccine-associated case of paralytic poliomyelitis in Brazil. Brazilian Journal of Medical and Biological Research, 29: 15-18.
87. Friedrich F, Da-Silva EE & Schatzmayr HG (1996). Type 2 poliovirus recombinants isolated from vaccine-associated cases and from healthy contacts in Brazil. Acta Virologica, 40: 27-33.
88. Kinnunen E, Färkkilä M, Hovi T, Juntunen J & Weckström P (1989). Incidence of Guillain-Barré syndrome during a nationwide oral poliovirus vaccine campaign. Neurology, 39: 1034-1036.
89. Uhari M, Rantala H & Niemelä M (1989). Cluster of childhood Guillain-Barré cases after an oral poliovaccine campaign. Lancet 2: 440-441.
90. Stratton KR, Howe CJ & Johnston RB (1994). Adverse events associated with childhood vaccines other than pertussis and rubella. Journal of the American Medical Association, 271: 1602-1605.
91. Poliomielite: Informe Semanal, ano VI no 19 (1991). Ministério da Saúde, Brasília, DF.
92. Friedrich F, Filippis AMB, Ferreira FC, Schatzmayr HG & Da-Silva EE (1995). Genomic characterization of type 1 Sabin-related polioviruses isolated in Brazil. Acta Virologica, 39: 23-29.
93. Friedrich F, Filippis AMB & Schatzmayr HG (1995). Sabin-related poliovirus vaccine strains isolated from transverse myelitis cases in Brazil. Revista do Instituto de Medicina Tropical de São Paulo, 37: 543-545.
94. Friedrich F, Filippis AMB & Schatzmayr HG (1996). Temporal association between the isolation of Sabin-related poliovirus vaccine strains and the Guillain-Barré syndrome. Revista do Instituto de Medicina Tropical de São Paulo, 38: 55-58.
95. Ehrengut W (1996). Relationship of oral poliovirus vaccine administration to Guillain-Barré syndrome. Acta Paediatrica Japonica, 38: 423.
96. Poliomielite: Informe Semanal ano VI No. 33 (1991). Ministério da Saúde, Brasília, DF.
97. Colbère-Garapin F, Christodoulou C, Crainic R & Pelletier I (1989). Persistent poliovirus infection of human neuroblastoma cells. Proceedings of the National Academy of Sciences, USA, 86: 7590-7594.
98. Pelletier I, Couderc T, Borzakian S, Wyckoff E, Crainic R, Ehrenfeld E & Colbère-Garapin F (1991). Characterization of persistent poliovirus mutants selected in human neuroblastoma cells. Virology, 180: 729-737.
99. Borzakian S, Pelletier I, Calvez V & Colbère-Garapin F (1993). Precise missense and silent point mutations are fixed in the genomes of poliovirus mutants from persistently infected cells. Journal of Virology, 67: 2914-2917.
100. Pavio N, Buc-Caron MH & Colbère-Garapin F (1996). Persistent poliovirus infection of human fetal brain cells. Journal of Virology, 70: 6395-6401.
101. Muir P & Archard LC (1994). There is evidence for persistent enterovirus infections in chronic medical conditions in humans. Reviews in Medical Virology, 4: 245-250.
102. Muir P, Nicholson F, Sharief MK, Thompson EJ, Cairns NJ, Lantos P, Spencer GT, Kaminski HJ & Banatvala JE (1995). Evidence for persistent enterovirus infection of the central nervous system in patients with previous paralytic poliomyelitis. Annals of the New York Academy of Sciences, 753: 219-232.
103. Johnson RT (1995). Pathogenesis of poliovirus infections. Annals of the New York Academy of Sciences. 753: 361-365.
104. Leon-Monzon ME & Dalakas MC (1995). Detection of poliovirus antibodies and poliovirus genome in patients with the post-polio syndrome. Annals of the New York Academy of Sciences, 753: 208-218.
105. Leparc-Goffart I, Julien J, Fuchs F, Janatova I, Aymard M & Kopecka H (1996). Evidence of presence of poliovirus genomic sequences in cerebrospinal fluid from patients with post-polio syndrome. Journal of Clinical Microbiology, 34: 2023-2026.
106. Eichner M & Dietz K (1996). Eradication of poliomyelitis: When can one be sure that poliovirus transmission has been terminated? American Journal of Epidemiology, 143: 816-822.
107. Castrignano SB (1996). Resposta de portadores de deficiência de IgA à vacina oral contra a poliomielite: avaliação clinica e análise laboratorial da produção de anticorpos séricos e secretórios. Doctoral thesis. Medicina/USP.
108. Waldman EA, Moreira RC, Saez SG, Souza DFC, Carmona RCC, Takimoto S & Cortes VA (1996). Human enterovirus infection in stray dogs. Some aspects of interest to Public Health. Revista do Institute de Medicine Tropical de São Paulo, 38: 157-161.
109. Koike S, Horie H, Sato Y, Ise I, Taya C, Nomura T, Yoshioka I, Yonekawa H & Nomoto A (1993). Poliovirus-sensitive transgenic mice as a new animal model. Developments in Biological Standardization, 78: 101-107.
110. Racaniello VR, Ren R & Bouchard M (1993). Poliovirus attenuation and pathogenesis in a transgenic mouse model for poliomyelitis. Developments in Biological Standardization, 78: 109-116.